Key Highlights

  • VCI Global (NASDAQ:VCIG) slid 31.37% to USD 5.60 after its 1-for-18 reverse split took effect.
  • J and Friends Holdings (NASDAQ:JF) fell 25.52% to USD 0.7001 with no announcement identified.
  • Jaguar Health (NASDAQ:JAGX) dropped 25.05% to USD 0.6626 ahead of a November 6, 2026 stockholder vote on a Debt exchange.
  • Haoxin Holdings (NASDAQ:HXHX) sank 22.42% to USD 0.1831 after a notice about broker order requirements.
  • Adeia (NASDAQ:ADEA) lost 22.11% to USD 16.10 after third quarter Revenue fell and its 2026 outlook was lowered.

VCI Global (NASDAQ:VCIG) (down USD 2.56, 31.37%): Sliding After a 1-for-18 Reverse Split

VCI Global (NASDAQ:VCIG) fell 31.37% to USD 5.60 in pre-market trading on November 3, 2026. No separate announcement dated November 2 or November 3, 2026 was identified. A 1-for-18 reverse share split took effect at 12:01 a.m. Eastern Time on November 2, 2026, reducing shares outstanding from about 9,639,594 to about 535,533.

The company said the split aims to satisfy the Nasdaq minimum bid price and position it for a potential "landmark institutional transaction", which it did not describe. It has consolidated shares more than once before. With so few shares expected to remain, thin trading can make pre-market quotes unreliable.

J and Friends Holdings (NASDAQ:JF) (down USD 0.2399, 25.52%): A Penny Stock Retreats Without Fresh News

J and Friends Holdings (NASDAQ:JF), a penny stock, dropped 25.52% to USD 0.7001 in pre-market trading on November 3, 2026, from a close of about USD 0.94. No company announcement from the past several days was identified, so the cause remains unconfirmed. A data provider lists the next Earnings date as November 6, 2026, which the company had not confirmed.

The company supplies software to small and medium hospitality merchants in Australia and was previously listed as PT under the name Pintec Technology Holdings. Full-year 2025 revenue was about USD 1.6 million with a net loss of about USD 1.3 million. A USD 150 million shelf registration filed on April 27, 2026 leaves room for possible dilution.

Jaguar Health (NASDAQ:JAGX) (down USD 0.2215, 25.05%): Falling Ahead of a Debt-for-Equity Vote

Jaguar Health (NASDAQ:JAGX), a penny stock, declined 25.05% to USD 0.6626 in pre-market trading on November 3, 2026. No same-day company announcement was identified. A special stockholder meeting on November 6, 2026 will vote on exchanging about USD 2.9 million of debt and preferred stock for common stock.

At an illustrative minimum price of USD 7.06, a full exchange would issue 3,596,425 shares, while only 1,945,542 shares were outstanding as of September 25, 2026. A lower price would mean many more shares. The company develops plant-based prescription medicines, led by Mytesi, and filed a USD 75 million mixed securities shelf on October 22, 2026. Dilution and listing risk remain central.

Haoxin Holdings (NASDAQ:HXHX) (down USD 0.0529, 22.42%): Dropping After a Broker Order Notice

Haoxin Holdings (NASDAQ:HXHX), a penny stock, fell 22.42% to USD 0.1831 in pre-market trading on November 3, 2026. A company release dated November 2, 2026 said some Brokers may require investors to place orders through a broker representative. The company did not link the notice to any price move, so the connection is an inference.

Haoxin provides temperature-controlled truckload and urban delivery services in mainland China. It received a Nasdaq bid-price notice in December 2025, and a 180-day extension appeared in a July 24, 2026 filing. The company has said it may consider a reverse stock split, and convertible notes, an Equity line and warrants can lead to dilution.

Adeia (NASDAQ:ADEA) (down USD 4.57, 22.11%): Third Quarter Revenue Falls and Guidance Is Lowered

Adeia (NASDAQ:ADEA) lost 22.11% to USD 16.10 in pre-market trading on November 3, 2026. The move follows its third quarter report released on November 2, 2026, with revenue of USD 80.2 million compared with USD 87.3 million a year earlier. Full-year 2026 revenue guidance was reduced to USD 375.0 million to USD 415.0 million from USD 395.0 million to USD 435.0 million.

Management said the timing of a few deals could push some revenue beyond year-end. The company licenses patented technology across semiconductors, consumer electronics and streaming. A licensing model tied to negotiation timing and legal outcomes can produce uneven quarterly revenue. Term Loan principal outstanding was USD 386.5 million.

Where Things Stand

Only Adeia has a clear earnings catalyst. VCI Global, Jaguar Health and Haoxin Holdings are tied to share count mechanics, dilution or listing questions, and J and Friends Holdings fell without an identified announcement. Track the November 6, 2026 Jaguar Health meeting, any Nasdaq correspondence for the penny stocks here, J and Friends Holdings results if a date is confirmed, and Adeia's deal closings in the fourth quarter.